A key Re­pub­li­can con­gress­man asked the Trump ad­min­is­tra­tion to re­strict the stream of mon­ey in­to Chi­na’s biotech sec­tor, threat­en­ing to squelch the deal­mak­ing that’s be­come...

Gilead has at long last won US ap­proval of its he­pati­tis D treat­ment Hep­cludex, which the FDA pre­vi­ous­ly re­ject­ed over is­sues with its man­u­fac­tur­ing and...

An As­traZeneca breast can­cer drug re­ceived a pos­i­tive opin­ion from Eu­ro­pean reg­u­la­tors, de­spite an FDA ad­vi­so­ry com­mit­tee vot­ing against the drug last month. No­vo Nordisk’s...

Utah has re­leased ear­ly da­ta from a close­ly watched pro­gram that tests us­ing AI to re­new pre­scrip­tions for pa­tients with chron­ic con­di­tions.

Since mid-De­cem­ber, Doc­tron­ic...

The FDA has ap­proved the TROP2-di­rect­ed an­ti­body-drug con­ju­gate Da­troway as a first-line op­tion for triple-neg­a­tive breast can­cer, giv­ing Dai­ichi Sankyo and As­traZeneca a leg up...